About Amicogen
Amicogen is a company based in South Korea founded in 2000. The company has 223 employees. Amicogen operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter South Korea
- Employees 223
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website amicogen.com
- Social LinkedIn
- Legal Name Amicogen, Inc.
- Annual Revenue$29.07 M (USD)-75.82as on Dec 31, 2025
- Net Profit-$20.74 M (USD)43.25as on Dec 31, 2025
- EBITDA-$3.97 M (USD)-230.83as on Dec 31, 2025
- Employee Count223
IPO & Listings of Amicogen
Amicogen is a publicly listed company on the KRX with ticker symbol 092040 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Sep 2013
- Listed onKRX: 092040
- Listed entityAmicogen, Inc.
- Exchange sectorHealth technology
- ISINKR7092040005
- Share price986.00 KRW (-1.4% on the day) · 2026-10-08
- Market capitalisation69,466,909,134.00 KRW
- EPS (diluted, trailing year)-309.86 KRW
- Volume (last session)136,049
Financials of Amicogen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 41.98B KRW | -29.96B KRW | -5.74B KRW |
| 2024 | 173.60B KRW | -52.79B KRW | 4.39B KRW |
| 2023 | 159.90B KRW | -23.29B KRW | 11.95B KRW |
| 2022 | 144.30B KRW | -47.22B KRW | 7.74B KRW |
| 2021 | 124.88B KRW | 3.73B KRW | 6.14B KRW |
Detailed financial statements for Amicogen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Amicogen
Amicogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Amicogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Amicogen
The website of Amicogen (amicogen.com) receives about 10.9K visits a month and ranks #1,737,770 among all websites worldwide, #2,360 in Biotechnology and Pharmaceuticals.
- Monthly visits10.9K
▼ 16.7% vs previous month
- Unique visitors6.4K
per month
- Global rank#1,737,770
among all websites
- Category rank#2,360
Health · Biotechnology and Pharmaceuticals
- Bounce rate68%
- Pages per visit2.0
- Average visit12 sec
- DevicesDesktop 18% · Mobile 82%
Websites whose visitors overlap most with Amicogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharmnews.com | 100% | – | #274,610 | View details | |
| healthinnews.co.kr | 90% | – | – | View details | |
yakup.com | yakup.com | 90% | – | #118,603 | – |
| longchangchemical.com | 45% | 24.1K | #1,224,548 | View details |
Latest news on Amicogen
Complete news archive for Amicogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Amicogen
10 companies that operate in the same segment as Amicogen (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Amicogen
Amicogen was founded in 2000.
Amicogen is headquartered in South Korea.
Amicogen has 223 employees.
Annual revenue of Amicogen is $29.07M as on Dec 31, 2025.
Amicogen was founded in 2000 in South Korea and operates in the pharmaceutical and industrial biotechnology sectors. Enzymes, biological products, and purification solutions are developed and marketed by the company. Applications in human health are supported through items such as N-acetylglucosamine, pinitol, collagen, and chitosan. A protein A-based chromatographic resin is provided for antibody and protein purification. An enzyme range is offered for industrial biotechnology processes.
Amicogen's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Yes, Amicogen is publicly traded on KRX under the ticker symbol 092040.